Torrent Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 25, 2025, 8:02 pm

Market Cap	1,09,323 Cr.
Current Price	3,227
High / Low	3,591/2,755
Stock P/E	56.7
Book Value	224
Dividend Yield	0.99 %
ROCE	27.2 %
ROE	26.7 %
Face Value	5.00
PEG Ratio	6.42

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Torrent Pharmaceuticals Ltd

Competitors of Torrent Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.4 Cr.	55.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	37.7 Cr.	25.7	29.1/13.1	37.0	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,566.02 Cr	1,158.59		103.22	194.43	0.31%	16.65%	15.19%	6.18

All Competitor Stocks of Torrent Pharmaceuticals Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	2,131	2,347	2,291	2,491	2,491	2,591	2,660	2,732	2,745	2,859	2,889	2,809	2,959
Expenses	1,570	1,635	1,612	1,767	1,764	1,800	1,835	1,863	1,862	1,955	1,950	1,895	1,995
Operating Profit	561	712	679	724	727	791	825	869	883	904	939	914	964
OPM %	26%	30%	30%	29%	29%	31%	31%	32%	32%	32%	32%	33%	33%
Other Income	-429	30	16	-10	9	34	26	55	31	24	-16	33	-42
Interest	57	55	69	102	107	103	91	80	80	75	64	57	56
Depreciation	162	155	163	193	196	191	201	213	203	197	198	199	201
Profit before tax	-87	532	463	419	433	531	559	631	631	656	661	691	665
Tax %	36%	33%	33%	30%	34%	29%	31%	30%	29%	30%	31%	27%	25%
Net Profit	-118	354	312	292	287	378	386	443	449	457	453	503	498
EPS in Rs	-3.49	10.46	9.22	8.63	8.48	11.17	11.41	13.09	13.27	13.50	13.39	14.86	14.71

Last Updated: May 31, 2025, 7:29 am

Below is a detailed analysis of the quarterly data for Torrent Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 2,959.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,809.00 Cr. (Dec 2024) to 2,959.00 Cr., marking an increase of 150.00 Cr..
For Expenses, as of Mar 2025, the value is 1,995.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,895.00 Cr. (Dec 2024) to 1,995.00 Cr., marking an increase of 100.00 Cr..
For Operating Profit, as of Mar 2025, the value is 964.00 Cr.. The value appears strong and on an upward trend. It has increased from 914.00 Cr. (Dec 2024) to 964.00 Cr., marking an increase of 50.00 Cr..
For OPM %, as of Mar 2025, the value is 33.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 33.00%.
For Other Income, as of Mar 2025, the value is -42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Dec 2024) to -42.00 Cr., marking a decrease of 75.00 Cr..
For Interest, as of Mar 2025, the value is 56.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 57.00 Cr. (Dec 2024) to 56.00 Cr., marking a decrease of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 201.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 199.00 Cr. (Dec 2024) to 201.00 Cr., marking an increase of 2.00 Cr..
For Profit before tax, as of Mar 2025, the value is 665.00 Cr.. The value appears to be declining and may need further review. It has decreased from 691.00 Cr. (Dec 2024) to 665.00 Cr., marking a decrease of 26.00 Cr..
For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Dec 2024) to 25.00%, marking a decrease of 2.00%.
For Net Profit, as of Mar 2025, the value is 498.00 Cr.. The value appears to be declining and may need further review. It has decreased from 503.00 Cr. (Dec 2024) to 498.00 Cr., marking a decrease of 5.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 14.71. The value appears to be declining and may need further review. It has decreased from 14.86 (Dec 2024) to 14.71, marking a decrease of 0.15.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:41 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	4,172	4,636	6,687	5,816	5,950	7,673	7,939	8,005	8,508	9,620	10,728	11,516
Expenses	3,216	3,616	3,954	4,438	4,601	5,690	5,769	5,524	6,077	6,778	7,360	7,795
Operating Profit	955	1,020	2,733	1,377	1,349	1,983	2,170	2,480	2,431	2,842	3,368	3,721
OPM %	23%	22%	41%	24%	23%	26%	27%	31%	29%	30%	31%	32%
Other Income	34	286	32	223	299	-300	121	57	-288	45	146	-1
Interest	59	175	184	206	308	504	451	353	255	333	354	252
Depreciation	87	191	238	307	409	618	654	658	662	707	808	795
Profit before tax	844	940	2,343	1,088	931	562	1,187	1,526	1,226	1,847	2,352	2,673
Tax %	21%	20%	26%	14%	27%	22%	14%	18%	37%	33%	30%	29%
Net Profit	664	751	1,733	934	678	436	1,025	1,252	777	1,245	1,656	1,911
EPS in Rs	19.62	22.19	51.22	27.59	20.04	12.89	30.28	36.99	22.97	36.79	48.94	56.47
Dividend Payout %	25%	25%	34%	25%	35%	66%	53%	47%	105%	60%	57%	57%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	13.10%	130.76%	-46.11%	-27.41%	-35.69%	135.09%	22.15%	-37.94%	60.23%	33.01%	15.40%
Change in YoY Net Profit Growth (%)	0.00%	117.66%	-176.86%	18.70%	-8.28%	170.78%	-112.95%	-60.09%	98.17%	-27.22%	-17.61%

Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	10%
5 Years:	8%
3 Years:	11%
TTM:	7%

Compounded Profit Growth
10 Years:	10%
5 Years:	14%
3 Years:	21%
TTM:	22%

Stock Price CAGR
10 Years:	17%
5 Years:	21%
3 Years:	31%
1 Year:	15%

Return on Equity
10 Years:	23%
5 Years:	23%
3 Years:	24%
Last Year:	27%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:11 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	85	85	85	85	85	85	85	85	85	169	169	169
Reserves	1,818	2,406	3,409	4,266	4,538	4,640	4,739	5,753	5,868	6,029	6,687	7,422
Borrowings	1,132	2,740	2,352	2,510	6,462	6,038	5,784	4,874	4,070	5,369	4,022	3,202
Other Liabilities	1,988	2,589	3,040	2,740	3,159	3,351	3,402	3,363	2,884	3,043	3,627	4,197
Total Liabilities	5,022	7,820	8,886	9,601	14,243	14,113	14,010	14,075	12,906	14,610	14,505	14,990
Fixed Assets	875	2,833	2,859	3,688	7,855	7,748	7,533	7,065	6,423	8,121	8,138	8,057
CWIP	534	678	1,042	519	647	617	712	889	630	765	361	367
Investments	186	298	780	804	492	353	2	181	226	199	173	156
Other Assets	3,427	4,011	4,206	4,589	5,249	5,395	5,763	5,940	5,628	5,524	5,834	6,410
Total Assets	5,022	7,820	8,886	9,601	14,243	14,113	14,010	14,075	12,906	14,610	14,505	14,990

Below is a detailed analysis of the balance sheet data for Torrent Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 169.00 Cr..
For Reserves, as of Mar 2025, the value is 7,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,687.00 Cr. (Mar 2024) to 7,422.00 Cr., marking an increase of 735.00 Cr..
For Borrowings, as of Mar 2025, the value is 3,202.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4,022.00 Cr. (Mar 2024) to 3,202.00 Cr., marking a decrease of 820.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 4,197.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,627.00 Cr. (Mar 2024) to 4,197.00 Cr., marking an increase of 570.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 14,990.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,505.00 Cr. (Mar 2024) to 14,990.00 Cr., marking an increase of 485.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 8,057.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,138.00 Cr. (Mar 2024) to 8,057.00 Cr., marking a decrease of 81.00 Cr..
For CWIP, as of Mar 2025, the value is 367.00 Cr.. The value appears strong and on an upward trend. It has increased from 361.00 Cr. (Mar 2024) to 367.00 Cr., marking an increase of 6.00 Cr..
For Investments, as of Mar 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2024) to 156.00 Cr., marking a decrease of 17.00 Cr..
For Other Assets, as of Mar 2025, the value is 6,410.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,834.00 Cr. (Mar 2024) to 6,410.00 Cr., marking an increase of 576.00 Cr..
For Total Assets, as of Mar 2025, the value is 14,990.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,505.00 Cr. (Mar 2024) to 14,990.00 Cr., marking an increase of 485.00 Cr..

Notably, the Reserves (7,422.00 Cr.) exceed the Borrowings (3,202.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	599	810	2,742	1,009	894	1,798	1,393	2,005	1,803	2,368	3,266	2,585
Cash from Investing Activity +	-418	-2,113	-869	-798	-4,677	-246	229	-444	-196	-2,335	-160	-540
Cash from Financing Activity +	86	1,212	-1,435	-193	3,417	-1,314	-1,549	-1,651	-1,781	77	-2,780	-2,298
Net Cash Flow	268	-90	437	18	-366	238	73	-89	-174	110	327	-253

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	954.00	-1.00	0.00	-1.00	-5.00	-5.00	-3.00	-2.00	-2.00	-3.00	-1.00	0.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	78	96	125	79	60	77	68	76	69	70	74	63
Inventory Days	364	297	275	314	318	429	318	362	456	368	298	310
Days Payable	421	421	472	523	356	447	345	345	351	250	224	284
Cash Conversion Cycle	22	-28	-71	-130	21	59	42	93	174	188	147	89
Working Capital Days	33	42	54	-1	28	20	-17	-2	82	89	74	53
ROCE %	33%	35%	27%	48%	19%	13%	13%	15%	17%	19%	20%	23%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	71.25%	68.31%
FIIs	10.88%	10.80%	11.37%	12.09%	12.04%	12.85%	13.15%	14.08%	14.14%	14.22%	14.46%	16.17%
DIIs	9.74%	10.01%	9.40%	8.77%	8.89%	8.22%	7.91%	7.11%	7.15%	7.17%	6.98%	8.25%
Government	0.00%	0.00%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%	0.10%
Public	8.14%	7.95%	7.87%	7.78%	7.71%	7.59%	7.59%	7.46%	7.34%	7.25%	7.21%	7.17%
No. of Shareholders	63,229	62,933	67,866	65,237	63,831	61,572	69,612	69,117	71,154	74,765	79,848	85,035

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Kotak Emerging Equity Fund - Regular Plan	2,309,253	1.5	584.5	2,309,253	2025-04-22 17:25:17	0%
UTI Flexi Cap Fund	1,233,512	1.24	312.21	1,233,512	2025-04-22 17:25:17	0%
SBI Large & Midcap Fund	740,002	0.94	187.3	740,002	2025-04-22 17:25:17	0%
Nippon India Pharma Fund	603,364	2.22	152.72	603,364	2025-04-22 17:25:17	0%
Kotak Small Cap Fund - Regular Plan	463,748	0.81	117.38	463,748	2025-04-22 17:25:17	0%
Axis Growth Opportunities Fund	400,340	0.93	101.33	400,340	2025-04-22 17:25:17	0%
Kotak Equity Arbitrage Fund - Regular Plan	390,500	0.27	98.84	390,500	2025-04-22 17:25:17	0%
Nippon India Value Fund	353,626	1.28	89.51	353,626	2025-04-22 17:25:17	0%
Franklin India Bluechip Fund - Dividend	350,000	1.19	88.59	350,000	2025-04-22 17:25:17	0%
Franklin India Bluechip Fund - Growth	350,000	1.19	88.59	350,000	2025-04-22 17:25:17	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	56.47	48.94	36.79	45.93	73.98
Diluted EPS (Rs.)	56.47	48.94	36.79	45.93	73.98
Cash EPS (Rs.)	80.06	72.82	57.67	85.05	112.84
Book Value[Excl.RevalReserv]/Share (Rs.)	224.59	202.57	183.13	351.75	344.90
Book Value[Incl.RevalReserv]/Share (Rs.)	224.59	202.57	183.13	351.75	344.90
Revenue From Operations / Share (Rs.)	340.71	316.96	284.23	502.72	472.97
PBDIT / Share (Rs.)	110.77	101.21	85.30	155.27	149.90
PBIT / Share (Rs.)	87.25	77.33	64.43	116.15	111.04
PBT / Share (Rs.)	79.08	69.49	54.58	72.44	90.18
Net Profit / Share (Rs.)	56.54	48.94	36.79	45.92	73.97
NP After MI And SOA / Share (Rs.)	56.54	48.94	36.79	45.92	73.97
PBDIT Margin (%)	32.51	31.93	30.01	30.88	31.69
PBIT Margin (%)	25.60	24.39	22.66	23.10	23.47
PBT Margin (%)	23.21	21.92	19.20	14.40	19.06
Net Profit Margin (%)	16.59	15.44	12.94	9.13	15.63
NP After MI And SOA Margin (%)	16.59	15.44	12.94	9.13	15.63
Return on Networth / Equity (%)	25.17	24.15	20.09	13.05	21.44
Return on Capital Employeed (%)	28.70	27.16	22.79	22.63	20.46
Return On Assets (%)	12.74	10.99	8.29	5.93	8.89
Long Term Debt / Equity (X)	0.15	0.23	0.40	0.35	0.50
Total Debt / Equity (X)	0.39	0.57	0.85	0.67	0.82
Asset Turnover Ratio (%)	0.76	0.71	0.68	0.53	0.50
Current Ratio (X)	1.19	1.03	0.97	1.20	1.13
Quick Ratio (X)	0.65	0.61	0.56	0.64	0.58
Inventory Turnover Ratio (X)	0.63	0.73	0.63	0.68	0.69
Dividend Payout Ratio (NP) (%)	0.00	61.29	69.30	87.09	27.03
Dividend Payout Ratio (CP) (%)	0.00	41.19	44.21	47.02	17.72
Earning Retention Ratio (%)	0.00	38.71	30.70	12.91	72.97
Cash Earning Retention Ratio (%)	0.00	58.81	55.79	52.98	82.28
Interest Coverage Ratio (X)	14.86	9.69	8.66	10.30	7.19
Interest Coverage Ratio (Post Tax) (X)	8.68	5.43	4.73	5.95	4.55
Enterprise Value (Cr.)	111776.48	91136.90	56758.99	50939.27	47229.23
EV / Net Operating Revenue (X)	9.71	8.50	5.90	5.99	5.90
EV / EBITDA (X)	29.85	26.60	19.66	19.38	18.62
MarketCap / Net Operating Revenue (X)	9.49	8.21	5.41	5.56	5.37
Retention Ratios (%)	0.00	38.70	30.69	12.90	72.96
Price / BV (X)	14.40	12.84	8.39	7.95	7.37
Price / Net Operating Revenue (X)	9.49	8.21	5.41	5.56	5.37
EarningsYield	0.01	0.01	0.02	0.01	0.02

After reviewing the key financial ratios for Torrent Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
For Diluted EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
For Cash EPS (Rs.), as of Mar 25, the value is 80.06. This value is within the healthy range. It has increased from 72.82 (Mar 24) to 80.06, marking an increase of 7.24.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.59. It has increased from 202.57 (Mar 24) to 224.59, marking an increase of 22.02.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.59. It has increased from 202.57 (Mar 24) to 224.59, marking an increase of 22.02.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.71. It has increased from 316.96 (Mar 24) to 340.71, marking an increase of 23.75.
For PBDIT / Share (Rs.), as of Mar 25, the value is 110.77. This value is within the healthy range. It has increased from 101.21 (Mar 24) to 110.77, marking an increase of 9.56.
For PBIT / Share (Rs.), as of Mar 25, the value is 87.25. This value is within the healthy range. It has increased from 77.33 (Mar 24) to 87.25, marking an increase of 9.92.
For PBT / Share (Rs.), as of Mar 25, the value is 79.08. This value is within the healthy range. It has increased from 69.49 (Mar 24) to 79.08, marking an increase of 9.59.
For Net Profit / Share (Rs.), as of Mar 25, the value is 56.54. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.54, marking an increase of 7.60.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 56.54. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.54, marking an increase of 7.60.
For PBDIT Margin (%), as of Mar 25, the value is 32.51. This value is within the healthy range. It has increased from 31.93 (Mar 24) to 32.51, marking an increase of 0.58.
For PBIT Margin (%), as of Mar 25, the value is 25.60. This value exceeds the healthy maximum of 20. It has increased from 24.39 (Mar 24) to 25.60, marking an increase of 1.21.
For PBT Margin (%), as of Mar 25, the value is 23.21. This value is within the healthy range. It has increased from 21.92 (Mar 24) to 23.21, marking an increase of 1.29.
For Net Profit Margin (%), as of Mar 25, the value is 16.59. This value exceeds the healthy maximum of 10. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.59. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
For Return on Networth / Equity (%), as of Mar 25, the value is 25.17. This value is within the healthy range. It has increased from 24.15 (Mar 24) to 25.17, marking an increase of 1.02.
For Return on Capital Employeed (%), as of Mar 25, the value is 28.70. This value is within the healthy range. It has increased from 27.16 (Mar 24) to 28.70, marking an increase of 1.54.
For Return On Assets (%), as of Mar 25, the value is 12.74. This value is within the healthy range. It has increased from 10.99 (Mar 24) to 12.74, marking an increase of 1.75.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. It has decreased from 0.23 (Mar 24) to 0.15, marking a decrease of 0.08.
For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.57 (Mar 24) to 0.39, marking a decrease of 0.18.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has increased from 0.71 (Mar 24) to 0.76, marking an increase of 0.05.
For Current Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 1.5. It has increased from 1.03 (Mar 24) to 1.19, marking an increase of 0.16.
For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.65, marking an increase of 0.04.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 4. It has decreased from 0.73 (Mar 24) to 0.63, marking a decrease of 0.10.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 61.29 (Mar 24) to 0.00, marking a decrease of 61.29.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 41.19 (Mar 24) to 0.00, marking a decrease of 41.19.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 38.71 (Mar 24) to 0.00, marking a decrease of 38.71.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 58.81 (Mar 24) to 0.00, marking a decrease of 58.81.
For Interest Coverage Ratio (X), as of Mar 25, the value is 14.86. This value is within the healthy range. It has increased from 9.69 (Mar 24) to 14.86, marking an increase of 5.17.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.68. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 8.68, marking an increase of 3.25.
For Enterprise Value (Cr.), as of Mar 25, the value is 111,776.48. It has increased from 91,136.90 (Mar 24) to 111,776.48, marking an increase of 20,639.58.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.71. This value exceeds the healthy maximum of 3. It has increased from 8.50 (Mar 24) to 9.71, marking an increase of 1.21.
For EV / EBITDA (X), as of Mar 25, the value is 29.85. This value exceeds the healthy maximum of 15. It has increased from 26.60 (Mar 24) to 29.85, marking an increase of 3.25.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.49. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.49, marking an increase of 1.28.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 38.70 (Mar 24) to 0.00, marking a decrease of 38.70.
For Price / BV (X), as of Mar 25, the value is 14.40. This value exceeds the healthy maximum of 3. It has increased from 12.84 (Mar 24) to 14.40, marking an increase of 1.56.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.49. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.49, marking an increase of 1.28.
For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Torrent Pharmaceuticals Ltd as of June 26, 2025 is: 2,739.75

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 26, 2025, Torrent Pharmaceuticals Ltd is Overvalued by 15.10% compared to the current share price 3,227.00

Intrinsic Value of Torrent Pharmaceuticals Ltd as of June 26, 2025 is: 2,981.66

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 26, 2025, Torrent Pharmaceuticals Ltd is Overvalued by 7.60% compared to the current share price 3,227.00

Last 5 Year EPS CAGR: 8.83%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 23.50%, which is a positive sign. The company has higher reserves (4,797.92 cr) compared to borrowings (4,046.25 cr), indicating strong financial stability. The company has shown consistent growth in sales (7.00 cr) and profit (274.00 cr) over the years.	The stock has a high average Working Capital Days of 37.92, which may not be favorable. The stock has a high average Cash Conversion Cycle of 50.50, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Torrent Pharmaceuticals Ltd:
1. Net Profit Margin: 16.59%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 28.7% (Industry Average ROCE: 16.65%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 25.17% (Industry Average ROE: 15.19%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 8.68
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.65
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 56.7 (Industry average Stock P/E: 103.22)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.39
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 9682.00 Cr. and Equity Capital is Rs. 169.00 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Torrent House, Off Ashram Road, Ahmedabad Gujarat 380009	investorservices@torrentpharma.com http://www.torrentpharma.com

Management
Name	Position Held
Mr. Sudhir Mehta	Chairman Emeritus
Mr. Samir Mehta	Executive Chairman
Mr. Aman Samir Mehta	Whole Time Director
Mr. Jinesh Shah	Director - Operations
Mr. Jinal Mehta	Non Executive Director
Mr. Manish Mahendra Choksi	Independent Director
Dr. Maurice Chagnaud	Independent Director
Mr. Nikhil Khattau	Independent Director
Ms. Ameera Shah	Independent Director
Ms. Nayantara Bali	Independent Director

FAQ

What is the intrinsic value of Torrent Pharmaceuticals Ltd?

Torrent Pharmaceuticals Ltd's intrinsic value (as of 25 June 2025) is ₹2739.75 — 15.10% lower the current market price of 3,227.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,09,323 Cr. market cap, FY2025-2026 high/low of ₹3,591/2,755, reserves of 7,422 Cr, and liabilities of 14,990 Cr.

What is the Market Cap of Torrent Pharmaceuticals Ltd?

The Market Cap of Torrent Pharmaceuticals Ltd is 1,09,323 Cr..

What is the current Stock Price of Torrent Pharmaceuticals Ltd as on 25 June 2025?

The current stock price of Torrent Pharmaceuticals Ltd as on 25 June 2025 is 3,227.

What is the High / Low of Torrent Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Torrent Pharmaceuticals Ltd stocks is ₹3,591/2,755.

What is the Stock P/E of Torrent Pharmaceuticals Ltd?

The Stock P/E of Torrent Pharmaceuticals Ltd is 56.7.

What is the Book Value of Torrent Pharmaceuticals Ltd?

The Book Value of Torrent Pharmaceuticals Ltd is 224.

What is the Dividend Yield of Torrent Pharmaceuticals Ltd?

The Dividend Yield of Torrent Pharmaceuticals Ltd is 0.99 %.

What is the ROCE of Torrent Pharmaceuticals Ltd?

The ROCE of Torrent Pharmaceuticals Ltd is 27.2 %.

What is the ROE of Torrent Pharmaceuticals Ltd?

The ROE of Torrent Pharmaceuticals Ltd is 26.7 %.

What is the Face Value of Torrent Pharmaceuticals Ltd?

The Face Value of Torrent Pharmaceuticals Ltd is 5.00.